Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 11/2015

01-11-2015 | Letter

Pancreatic triacylglycerol distribution in type 2 diabetes

Authors: Kieren G. Hollingsworth, Ahmad Al-Mrabeh, Sarah Steven, Roy Taylor

Published in: Diabetologia | Issue 11/2015

Login to get access

Excerpt

To the Editor: The paper by Begovatz and colleagues concluded that there was no fat in the parenchymal tissue of the pancreas, and hence local release of fatty acids could not influence endocrine function [1]. The authors describe intralobular fat within the pancreas as detected by spectroscopy but then concluded that there was no fat in the parenchyma of the pancreas. This conclusion relied upon magnetic resonance (MR) techniques. We draw attention to three serious errors in the MR methodology employed, and to the sound evidence for the existence of parenchymal fat. …
Literature
1.
Begovatz P, Koliaki C, Weber K et al (2015) Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans. Diabetologia 58:1646–1655CrossRefPubMed
2.
Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R (2011) Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54:2506–2514PubMedCentralCrossRefPubMed
3.
Hu HH, Kim HW, Nayak KS, Goran MI (2010) Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obesity 18:841–847PubMedCentralCrossRefPubMed
4.
Macauley M, Percival K, Thelwall PE, Hollingsworth KG, Taylor R (2015) Altered volume, morphology and composition of the pancreas in type 2 diabetes. PLoS One 10:e0126825PubMedCentralCrossRefPubMed
5.
Hollingsworth KG (2014) Quantitative MRI in muscular dystrophy: an indispensable trial endpoint? Neurology 83:956–957CrossRefPubMed
6.
Hollingsworth KG, Higgins DM, McCallum M, Ward L, Coombs A, Straub V (2014) Investigating the quantitative fidelity of prospectively undersampled chemical shift imaging in muscular dystrophy with compressed sensing and parallel imaging reconstruction. Magn Reson Med 72:1610–1619CrossRefPubMed
7.
Pinnick KE, Collins SC, Londos C, Gauguier D, Clark A, Fielding BA (2008) Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity 16:522–530CrossRefPubMed
8.
Lee Y, Lingvay I, Szczepaniak LS, Ravazzola M, Orci L, Unger RH (2010) Pancreatic steatosis: harbinger of type 2 diabetes in obese rodents. Int J Obes (Lond) 34:396–400CrossRef
9.
Lalloyer F, Vandewalle B, Percevault F et al (2006) Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 55:1605–1613CrossRefPubMed
10.
Dobbins RL, Szczepaniak LS, Myhill J et al (2002) The composition of dietary fat directly influences glucose-stimulated insulin secretion in rats. Diabetes 51:1825–1833CrossRefPubMed
Metadata
Title
Pancreatic triacylglycerol distribution in type 2 diabetes
Authors
Kieren G. Hollingsworth
Ahmad Al-Mrabeh
Sarah Steven
Roy Taylor
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 11/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3718-1

Other articles of this Issue 11/2015

Diabetologia 11/2015 Go to the issue

Article

Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice

Article

Fatty acids from fat cell lipolysis do not activate an inflammatory response but are stored as triacylglycerols in adipose tissue macrophages

Article

Plasma fatty acids as predictors of glycaemia and type 2 diabetes

Article

Insulin resistance is associated with poorer verbal fluency performance in women

Article

Low birthweight is associated with an increased risk of LADA and type 2 diabetes: results from a Swedish case–control study

Article

Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits